The funding will support research and development, device and app enhancements, manufacturing scale-up, and broader go-to-market execution.
Curapod by Litemed India, a Telangana-based startup, has raised INR 20 Cr (around USD 2.2 Mn) in a pre-Series A funding round led by V3 Ventures, 3i Partners and Ideaspring Capital, as it looks to scale its FDA-registered wearable devices for non-invasive musculoskeletal pain management.
The funding will support research and development, device and app enhancements, manufacturing scale-up, and broader go-to-market execution, as the start-up positions itself for sustained growth in the non-invasive care segment.
Sri Velliyur, Co-founder and CEO, Curapod, said the funding marks a critical milestone as the company focuses on pan-India expansion and positioning Curapod as a go-to solution for everyday pain management.
Surya Maguluri, Founder and CTO, added that the capital will enable deeper clinical engagement and continued innovation in non-invasive care.
Founded in 2022 by Sri Velliyur and Surya Maguluri, Curapod operates in the growing intersection of medical-grade wearables and consumer health. The startup develops non-invasive, light-therapy-based devices aimed at addressing musculoskeletal conditions, an area that continues to see high demand due to ageing populations, sedentary lifestyles, and rising sports-related injuries.
Curapod is backed by medical technology firm Litemed and follows a clinician-led adoption model to drive trust and long-term usage.
Its flagship device uses photobiomodulation therapy, including targeted red light wavelengths, to deliver drug-free pain relief. The FDA-registered wearable is designed to support more than 30 musculoskeletal conditions, including back pain, neck pain, knee pain, joint disorders, muscle stiffness, and sports injuries.
By offering a non-pharmacological alternative, Curapod aims to reduce reliance on pain medications while enabling users to manage everyday discomfort and recovery more safely.
With the fresh capital, Curapod plans to strengthen its direct-to-consumer presence through wider marketplace launches and brand-building initiatives. At the same time, it intends to expand partnerships with gyms, physiotherapy centres, and sports medicine networks, creating multiple access points for patients and consumers.
Manufacturing scale-up and improvements in unit economics are also key priorities, as the company targets faster growth over the next year.
A portion of the funding will be allocated toward international expansion, with Curapod preparing for entry into European markets. This effort will be supported by regulatory readiness, additional clinical validation, and local market development, as the company explores opportunities beyond India.
Stay tuned for more such updates on Digital Health News
Source link
